Navigation Links
VIVUS Announces Sale of MUSE Assets to Meda

MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma company - for MUSE®, transurethral alprostadil, for the treatment of erectile dysfunction (ED).  Under the agreement, Meda will acquire the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.  As part of the transaction, the existing VIVUS employees that are MUSE dedicated, including the field sales force, are expected to join Meda. VIVUS will retain all of the liabilities associated with the pre-closing operations of the MUSE business.

"We have been business partners with Meda in Europe for MUSE since 2000 and the acquisition of MUSE fits with their expansion plans," stated Leland Wilson, chief executive officer of VIVUS.  "The divestiture of MUSE to Meda will allow us to focus on our commercialization efforts for QNEXA for obesity and development of avanafil for erectile dysfunction.  I appreciate all the efforts from those employees that have been involved with MUSE since its approval in late 1996.  As part of the Meda urology portfolio, we expect MUSE to continue to meet the needs of ED patients and their providers for years to come."

The acquisition price is $23.5 million, which includes an upfront cash payment of $22 million.  VIVUS is eligible to receive a one-time milestone payment of $1.5 million based on future sales of MUSE.  The transaction is subject to standard closing requirements and conditions.  The transaction is expected to close on or before November 15, 2010.

About MUSEIn 1997, VIVUS commercially launched MUSE in the United States. MUSE was the first minimally invasive therapy for erectile dysfunction approved by the FDA. With MUSE, an erection is typically produced within 15 minutes of administration and lasts approximately 30 to 60 minutes. Alprostadil is the active pharmacologic agent used in MUSE. Alprostadil is the generic name for the synthetic version of prostaglandin E1, a naturally-occurring vasodilator present in the human body and at high levels in seminal fluid.

MUSE is designed to overcome the limitations of other available therapies through its unique product attributes. Because therapeutic levels of drug are delivered locally to the erectile tissues with minimal systemic drug exposure, MUSE is a relatively safe, local treatment that minimizes the chances of systemic interactions with other drugs or diseases. Because it mimics the normal vasoactive process, MUSE produces an erection that is more natural than those resulting from needle injection therapy, vacuum constriction devices or penile implants.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.CONTACT:VIVUS, Inc.Investor Relations:Timothy E. MorrisThe Trout GroupChief Financial Officer

Brian Korb650-934-5200


Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
2. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
3. VIVUS to Present at Lazard Capital Markets Healthcare Conference
4. VIVUS Announces Promotion of Peter Tam to President
5. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
6. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
7. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
8. NCPA Announces New Division Dedicated to Long-Term Care Pharmacies, Patients
9. Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan
10. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
11. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
Post Your Comments:
(Date:12/1/2015)... and TELTOW, Germany , ... Instruments (SMI) , a leading global manufacturer of eye ... LLC has included SMI remote eye trackers as ... help healthcare providers assess concussions, eye sight, and medical ... RED -oem technology is part of SMI,s mass-market-ready eye ...
(Date:12/1/2015)... , December 1, 2015 ... Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL), among ... has acquired Elekta,s Leksell Gamma Knife® Icon™, the ... brain. --> --> ... or traditional frame-based treatments, Leksell Gamma Knife Icon ...
(Date:12/1/2015)... 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast to ... ) has announced the addition of ... Forecast to 2020" report to their offering. ... ) has announced the addition of the ...
Breaking Medicine Technology:
(Date:12/1/2015)... TX (PRWEB) , ... December 01, 2015 , ... Dr. ... of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single ... of the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... 2015 , ... December 1, 2015 -- InstantLabs is adding ... product line of food safety and seafood fraud prevention tools. , The new ... InstantLabs to offer fast, reliable species identification for the four most popular salmon. ...
(Date:12/1/2015)... ... 2015 , ... It’s official: Tattoo taboo is a thing of the past. ... Millennials (a whopping one in three aged 18 to 25 is inked). As tattoos ... their ink. In fact, RealSelf , the world’s largest community for learning and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
Breaking Medicine News(10 mins):